Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 18/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118605 | 0.84 | PTGIR (0.72) | PTGIR | |
| SCHEMBL19715259 | 0.84 | PTGIR (0.72) | PTGIR | |
| SCHEMBL1118606 | 0.84 | PTGIR (0.72) | PTGIR | |
| SCHEMBL1118805 | 0.83 | PTGIR (0.56) | PTGIRCHRM3CHRM2CHRM1 | |
| SCHEMBL1118807 | 0.83 | PTGIR (0.56) | PTGIRCHRM3CHRM2CHRM1 | |
| SCHEMBL6519010 | 0.81 | PTGIR (0.55) | PTGIRCHRM3 | |
| SCHEMBL1118739 | 0.81 | PTGIR (0.55) | PTGIRCHRM3 | |
| SCHEMBL19715261 | 0.78 | PTGIR (0.56) | PTGIRCHRM3CHRM2CHRM1 | |
| SCHEMBL30325319 | 0.78 | PTGIR (0.56) | PTGIRCHRM3CHRM2CHRM1 | |
| SCHEMBL15195059 | 0.77 | PTGIR (0.60) | PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217706-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, PTGER2 | PTGIR 1/4885CHRM3 1275/4885CHRM2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.